Citations

Clear

9985 citation(s) found for "Ou, San-San".

Large language model-powered endoscopic narrative system: a specialized vision–language model for endoscopic interpretation outperforms state-of-the-art generalist AI
Wang, Yichen , Zou, Yuntao , Wallace, Michael B , Kumbhari, Vivek , Huang, Yuting

Mayo Clinic

Endoscopy | November 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2985-7910 | PMID 43057245 Get It

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Zanwar, Saurabh S , Hansen, Doris K , Tan, Carlyn R , Peres, Lauren C , Popat, Rakesh , Afrough, Aimaz , Asoori, Sireesha , Dave, Mrugakshi , Portuguese, Andrew J , Kastritis, Efstathios , Davis, James A , Martinez-Lopez, Joaquin , Sborov, Douglas W , Mihalyova, Jana , Bal, Susan , Janakiram, Murali , Ferreri, Christopher , Biran, Noa , Herr, Megan M. , Grajales-Cruz, Ariel F , Khouri, Jack , Castaneda Puglianini, Omar , Liang, Emily C , Zolotov, Eli , Galarza Fortuna, Gliceida M , Julian, Kelley L , Sannareddy, Aishwarya , Anderson, Larry D , Raza, Shahzad , Dima, Danai , Anwer, Faiz , Kumar, Shaji K , Usmani, Saad , Huang, Chiung-Yu , Mian, Hira , Sidana, Surbhi , Patel, Krina , Lin, Yi , Costa, Luciano J

Mayo Clinic

Journal of Clinical Oncology | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01039 | PMID 43024836 Get It

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Primary Amenorrhea: Diagnostic Approach, Imaging Spectrum, and Common Pitfalls
Trila, Maria Florencia , Mac Allister, Kevin K , Aineseder, Martina , Gomez, Erin N , Ainsworth, Alessandra J. , Jha, Priyanka , Kreindel, Tamara G , Poder, Liina , Causa Andrieu, Pamela

Mayo Clinic

RadioGraphics | November 12, 2026 | Volume: 46 | Issue: 12 | Pages: No page available

10.1148/rg.250140 | PMID 43019229 Get It

Primary amenorrhea reflects disruption along the hypothalamic-pituitary-ovarian-uterine axis; may arise from anatomic, genetic, or functional abnormalities; and may be diagnosed on the basis of US and MRI findings.
Predictors of learning the memory support system in individuals with amnestic mild cognitive impairment
Koay, Jun Min , Grant, Jeremy G , Aghamoosa, Stephanie , Shandera-Ochsner, Anne L, Chandler, Melanie J

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | November 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1080/13803395.2026.2762996 | PMID 43018120 Get It

Hyperaldosteronism Remission after Extended Aldosterone Synthase Inhibition
Brown, Morris Jonathan , Turcu, Adina F. , Sam, Ramin , Kirschner, Lawrence S. , Hamidi, Oksana , Eren, Aysegul, Ben-Shlomo, Anat , Huang, Wenyu , Bancos, Irina , Hamrahian, Amir Hekmat , Freeman, Mason W.

Mayo Clinic

New England Journal of Medicine | November 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1056/nejmc2611265 | PMID 43001732 Get It

Targeting NF-κB prevents Schwann cell reprogramming and plexiform neurofibroma initiation in mouse model of Nf1
Ravindran, Ramya , Youn, Eui-Kyung, Kedei, Noémi , Choi, Kwangmin , Volz, Avery, Dombi, Eva , Pundavela, Jay , Kim, MiOk, Spinner, Robert J. , Szabo, Sara , Largaespada, David A. , Shern, Jack F. , Ratner, Nancy

Mayo Clinic

No container title available | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.11.04.764357 Get It

Plexiform neurofibromas arise in approximately half of all individuals with Neurofibromatosis Type I (NF1). Genetic lesions apart from NF1 pathogenic variants are not present in NF1 mutant Schwann cells, suggesting that tumorigenesis may instead require cellular rewiring. To identify putatively re-wired tumor cells, we used multiplex imaging and flow cytometry to delineate markers that distinguish tumor Schwann cell from non-tumor Schwann cells. We identified tumor Schwann cells as CD44+;CD49f+ cells that show increased transcription of epithelial to mesenchymal plasticity (EMP)- associated genes. CD44+;CD49f+ expression was induced by treating Nf1-/- Schwann cells with stressors or by direct NF-κB pathway activation via IKK2; treated Schwann cells increased secretion of NF-κB targets and immune cell chemoattractants CCL2 and CCL3. In established tumors, MEK inhibition plus NF-κB blockade diminished tumor cell proliferation, tumor Schwann cells, immune cell populations, tumor cytokines and tumor number. Notably, transient single agent NF-κB pathway blockade was sufficient to significantly delay tumor formation in mice. Thus, Nf1 loss in Schwann cells is followed by NF-κB activation and cellular reprogramming that drives tumor initiation and targeting NF-κB activation can reduce NF1-deficient tumor formation.
Frequency and Phenotype of Coexisting Aquaporin‐4 and Autoimmune Encephalitis Autoantibodies
Cacciaguerra, Laura , Yang, Binxia, Lennon, Vanda A. , Agnihotri, Shruti P. , Ahsan, Nusrat , Fernández, Karen S. , McLeod, Erin, Mangioris, Georgios , Meador, William R., Mitchell, Wendy G. , Nicholas, Jacqueline A. , Quek, Amy M.L. , Shoemaker, Thomas , Sieloff, Kurt, Edmond, Matt C., Laggis, Rebekah A., Flynn, Kristin L., Waubant, Emmanuelle L. , Chen, John J., Irani, Sarosh R. , McKeon, Andrew , Ζεκερίδου, Αναστασία , Flanagan, Eoin P. , Pittock, Sean J. , Kunchok, Amy

Mayo Clinic

Annals of Clinical and Translational Neurology | November 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acn3.70541 | PMID 42979782 Get It

ABSTRACT Among 9457 aquaporin‐4 (AQP4) immunoglobulin G‐positive patients, 2071 underwent autoimmune encephalitis antibody testing and 85 (4%) had coexisting antibodies, most commonly cerebrospinal fluid glial fibrillary acidic protein‐IgG and N‐methyl‐D‐aspartate receptor‐IgG, or serum high‐titer GAD65‐IgG. Compared with AQP4‐IgG positive neuromyelitis optica spectrum disorder controls, dual‐positive patients were younger and more frequently exhibited encephalopathy, psychiatric symptoms, seizures, ovarian teratomas, and deep gray matter, temporal lobe, or diencephalic MRI abnormalities. GAD65‐IgG‐positive patients developed stiff‐person syndrome. These findings define a distinct mixed glial‐neuronal autoimmune phenotype and support additional neural antibody testing in atypical AQP4‐IgG‐positive presentations.
Cost-Effectiveness of Anterior and Posterior Surgical Approaches for Cervical Spondylotic Myelopathy: An Economic Evaluation of a Randomized Clinical Trial
Whitmore, Robert G. , Miranda, Stephen P. , Bydon, Mohamad , Dholakia, Ruchita, Moriarty, James P. , Borah, Bijan J. , Kanter, Adam S., Mummaneni, Praveen V. , Bisson, Erica F. , Harrop, James S., Magge, Subu N., Heary, Robert F., Fehlings, Michael G. , Albert, Todd J. , Arnold, Paul M., Riew, Kiehyun Daniel , Steinmetz, Michael P., Benzel, Edward, Wang, Marjorie C., Heller, John G., Ghogawala, Zoher

Mayo Clinic

Neurosurgery | November 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000004268 | PMID 42975416 Get It

BACKGROUND AND OBJECTIVES: Surgery for cervical spondylotic myelopathy improves quality of life but remains expensive. We conducted a cost-effectiveness analysis of patients treated with anterior cervical diskectomy/fusion (ACDF), posterior cervical decompression/fusion (PCDF), and laminoplasty (LP) in the Cervical Spondylotic Myelopathy Surgical (CSM-S) Trial, a randomized trial comparing surgical approaches for cervical spondylotic myelopathy. METHODS: In the trial, patients were randomized (2:3) to anterior (ACDF) or posterior surgery (LP or PCDF, at surgeon's discretion). A cost-effectiveness analysis was performed from a societal perspective with a 1-year time horizon, including only US patients as-treated. Cumulative costs were estimated using patient data on utilization and lost productivity using a human capital approach. Direct costs were calculated using 2022 Medicare rates for professional fees and cost-to-charge ratios for hospital services. Quality-adjusted life-years (QALYs) were calculated from patient responses to the EuroQol-5-Dimensions instrument at baseline and 3, 6, and 12 months postoperatively. Incremental cost-effectiveness ratio analysis was performed with bootstrapping to address uncertainty. RESULTS: Of 163 total patients enrolled in the CSM-S Trial, 153 from the United States (mean age, 62 years; 80 (52%) female) were included as-treated (ACDF = 61, PCDF = 64, LP = 28) in a cost-effectiveness analysis. Economic data were not available for 9 patients. The remaining 144 patients treated (ACDF = 55, PCDF = 61, LP = 28) had cost data through a 1-year follow-up. Mean hospitalization costs were higher after PCDF than ACDF and LP ($33 410 vs $26 468 vs $25 550; P < .001). Mean total costs were higher after PCDF than ACDF and LP ($62 383 vs $53 074 vs $47 426; P = .017). LP yielded greater QALY gains than ACDF (0.792 vs 0.732; P = .08) and PCDF (0.792 vs 0.698; P = .01). At a willingness-to-pay threshold of $150 000/QALY-gained, the probability that LP was cost-effective compared with PCDF was 99.7% and the probability compared with ACDF was 96%. CONCLUSION: In the CSM-S Trial, LP yielded greater 1-year quality-of-life improvements at lower costs than PCDF and ACDF.
Sudden Cardiac Death in Firefighters From the United States: A 16‐Year Postmortem Analysis
Petek, Bradley J , Layman, Andrew J. , Weller, Samantha L , Churchill, Timothy W , Shapiro, Michael D , Bhatia, Harpreet S , Baggish, Aaron L , Harmon, Kimberly G , Drezner, Jonathan A , Maleszewski, Joseph J , Kales, Stefanos

Mayo Clinic

Journal of the American Heart Association | October 30, 2026 | Volume: 15 | Issue: 21 | Pages: No page available

10.1161/jaha.126.051295 | PMID 42960733 Get It

Background Sudden cardiac death (SCD) is the leading cause of duty‐related death among firefighters. Understanding postmortem cardiovascular abnormalities associated with SCD is critical to guiding fire service cardiovascular disease screening and prevention programs. Methods This study included US firefighters who had a duty‐related death over a 16‐year period (1999–2014) with available postmortem reports (autopsy/medical examiner reports). Cases were systematically reviewed to identify cases of SCD. For each SCD case, the primary etiology of SCD was adjudicated by experts in sports cardiology and cardiovascular pathology. Results Postmortem evaluations were available for 794 of 2100 (37.8%) on‐duty firefighter deaths over the study period (average age, 44±13 years; age range, 17–82 years; 4.0% women). A total of 312 of 794 (39.3%) firefighter deaths were adjudicated as SCD. A total of 255 of 312 (81.8%) SCD events were attributable to coronary artery disease/ischemic heart disease or hypertensive heart disease, which both are associated with traditional cardiovascular risk factors. The leading etiology of SCD among young firefighters (aged <40 years) was also coronary artery disease/ischemic heart disease (24/50 [48.0%]). Of firefighters who had an exertional SCD event thought to be secondary to coronary artery disease (n=97), a total of 62 of 91 (68.1%) had severe fixed coronary stenosis, while 29 of 91 (31.9%) demonstrated acute plaque rupture/thrombosis. Conclusions More than 80% of on‐duty SCD events among US firefighters are due to coronary artery disease and hypertensive heart disease that may be prevented by early disease identification and risk factor modification. Future studies should assess the efficacy of more rigorous firefighter cardiovascular disease screening and management practices.
Reply to: Was Futility in RADICAL Robust to Analytic Specification?
McKay, Rana R , Ballman, Karla , Choueiri, Toni K

Mayo Clinic

Journal of Clinical Oncology | October 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-02352 | PMID 42945497 Get It